Accepted for Publication: July 25, 2012.
Published Online: October 15, 2012. doi:10.1001/2013.jamadermatol.541
Author Contributions: Drs Lessin and Y. H. Kim had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Lessin and Y. Kim. Acquisition of data: Lessin, Duvic, Guitart, Pandya, Strober, Olsen, Hull, Knobler, Rook, E. J. Kim, Naylor, Adelson, Kimball, Wood, Sundram, Wu, and Y. H. Kim. Analysis and interpretation of data: Lessin and Y. H. Kim. Drafting of the manuscript: Lessin, Duvic, Guitart, and Y. H. Kim. Critical revision of the manuscript for important intellectual content: Lessin, Duvic, Guitart, Pandya, Strober, Olsen, Hull, Knobler, Rook, E. J. Kim, Naylor, Adelson, Kimball, Wood, Sundram, Wu, and Y. H. Kim. Obtained funding: Lessin. Administrative, technical, and material support: Lessin, Sundram, Wu, and Y. H. Kim. Study supervision: Lessin.
Conflict of Interest Disclosures: Dr Lessin serves as a consultant to Ceptaris Therapeutics, Inc.
Funding/Support: This study was supported in part by grant R01 FD003017 from the Office of Orphan Products Development of the Food and Drug Administration (Dr Lessin) and by Ceptaris Therapeutics, Inc. Mechlorethamine, 0.02%, gel and mechlorethamine, 0.02%, ointment was provided by Ceptaris Therapeutics, Inc, through a contracted compounding pharmacy.
Role of the Sponsor: Ceptaris Therapeutics, Inc, monitored the conduct of the study and provided data collection and analysis.
Additional Contributions: Cathie A. Leister, MS, performed statistical analysis of the data. We thank our study patients for their participation and the Cutaneous Lymphoma Foundation for its grassroots support of this project.